Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab
Patients treated with B-cell-targeting therapies like Rituximab or Ibrutinib have decreased serological response to various vaccines. In this study, we tested serological and cellular response to SARS-CoV-2 mRNA vaccines in 16 patients treated with Ibrutinib, 16 treated with maintenance Rituximab, 1...
Saved in:
Published in | Clinical and experimental medicine Vol. 23; no. 2; pp. 371 - 379 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Cham
Springer International Publishing
01.06.2023
Springer Nature B.V |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Patients treated with B-cell-targeting therapies like Rituximab or Ibrutinib have decreased serological response to various vaccines. In this study, we tested serological and cellular response to SARS-CoV-2 mRNA vaccines in 16 patients treated with Ibrutinib, 16 treated with maintenance Rituximab, 18 patients with chronic lymphocytic leukaemia (CLL) with watch and wait status and 21 healthy volunteers. In comparison with the healthy volunteers, where serological response was achieved by 100% subjects, patients on B-cell-targeting therapy (Ibrutinib and Rituximab) had their response dramatically impaired. The serological response was achieved in 0% of Rituximab treated, 18% of Ibrutinib treated and 50% of untreated CLL patients. Cell-mediated immunity analysed by the whole blood Interferon-γ Release immune Assay developed in 80% of healthy controls, 62% of Rituximab treated, 75% of Ibrutinib treated and 55% of untreated CLL patients. The probability of cell-mediated immune response development negatively correlates with disease burden mainly in CLL patients. Our study shows that even though the serological response to SARS-CoV-2 vaccine is severely impaired in patients treated with B-cell-targeting therapy, the majority of these patients develop sufficient cell-mediated immunity. The vaccination of these patients therefore might be meaningful in terms of protection against SARS-CoV-2 infection. |
---|---|
AbstractList | Patients treated with B-cell-targeting therapies like Rituximab or Ibrutinib have decreased serological response to various vaccines. In this study, we tested serological and cellular response to SARS-CoV-2 mRNA vaccines in 16 patients treated with Ibrutinib, 16 treated with maintenance Rituximab, 18 patients with chronic lymphocytic leukaemia (CLL) with watch and wait status and 21 healthy volunteers. In comparison with the healthy volunteers, where serological response was achieved by 100% subjects, patients on B-cell-targeting therapy (Ibrutinib and Rituximab) had their response dramatically impaired. The serological response was achieved in 0% of Rituximab treated, 18% of Ibrutinib treated and 50% of untreated CLL patients. Cell-mediated immunity analysed by the whole blood Interferon-γ Release immune Assay developed in 80% of healthy controls, 62% of Rituximab treated, 75% of Ibrutinib treated and 55% of untreated CLL patients. The probability of cell-mediated immune response development negatively correlates with disease burden mainly in CLL patients. Our study shows that even though the serological response to SARS-CoV-2 vaccine is severely impaired in patients treated with B-cell-targeting therapy, the majority of these patients develop sufficient cell-mediated immunity. The vaccination of these patients therefore might be meaningful in terms of protection against SARS-CoV-2 infection. |
Author | Heizer, Tomas Novak, Jan Zubata, Ivana Mikesova, Marcela Kohutova, Zuzana Kucera, Petr Karel, Tomas Gaherova, Lubica Bacova, Barbora |
Author_xml | – sequence: 1 givenname: Barbora surname: Bacova fullname: Bacova, Barbora organization: Department of Haematology, 3RdFaculty of Medicine, Faculty Hospital Kralovske Vinohrady, Charles University, Central Laboratories of the Faculty Hospital Kralovske Vinohrady – sequence: 2 givenname: Zuzana surname: Kohutova fullname: Kohutova, Zuzana organization: Department of Haematology, 3RdFaculty of Medicine, Faculty Hospital Kralovske Vinohrady, Charles University – sequence: 3 givenname: Ivana surname: Zubata fullname: Zubata, Ivana organization: Department of Haematology, 3RdFaculty of Medicine, Faculty Hospital Kralovske Vinohrady, Charles University – sequence: 4 givenname: Lubica surname: Gaherova fullname: Gaherova, Lubica organization: Department of Haematology, 3RdFaculty of Medicine, Faculty Hospital Kralovske Vinohrady, Charles University – sequence: 5 givenname: Petr surname: Kucera fullname: Kucera, Petr organization: Department of Immunology and Clinical Biochemistry, 3Rd Faculty of Medicine, Charles University – sequence: 6 givenname: Tomas surname: Heizer fullname: Heizer, Tomas organization: Central Laboratories of the Faculty Hospital Kralovske Vinohrady – sequence: 7 givenname: Marcela surname: Mikesova fullname: Mikesova, Marcela organization: Central Laboratories of the Faculty Hospital Kralovske Vinohrady – sequence: 8 givenname: Tomas surname: Karel fullname: Karel, Tomas organization: Department of Statistics and Probability, Faculty of Informatics and Statistics, University of Economics and Business in Prague. Namesti W. Churchilla – sequence: 9 givenname: Jan orcidid: 0000-0003-1241-1635 surname: Novak fullname: Novak, Jan email: novakjan@centrum.cz organization: Department of Haematology, 3RdFaculty of Medicine, Faculty Hospital Kralovske Vinohrady, Charles University, Department of Immunology and Clinical Biochemistry, 3Rd Faculty of Medicine, Charles University |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35352210$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUtv1DAUhS1URB_wB1ggS2zYGPxMnA3SaMSjUgXSFNhajnPTcZXYg-209N_XMKUUFmxsy_e7x-f6HKODEAMg9JzR14zS9k1mlAtNKOeEUk07Qh-hI6Y6RjrF9cGD8yE6zvmSUqa0oE_QoVBCcc7oEbpewzQtk03YhgFvlzkmO2E_z0sAnCDvYsiAS8Tnq805WcdvhON582mFr6xzPkDGPuCdLR5CybgksAUGfO3LFkNdIOHTPi3FB9_jmPDGl-WHn23_FD0e7ZTh2d1-gr6-f_dl_ZGcff5wul6dESdbWcjIewVa8Ea2vOeaSSe4tHJwwnHbSjfycWSqGWgHzSDpYFVLZTf0qqmXjg7iBL3d6-6WfobBVZt1QLNL1US6MdF683cl-K25iFdGd43QWleBV3cCKX5fIBcz--zqp9kAccmmWlOyZaLhFX35D3oZlxTqeKZa77RimqlK8T3lUsw5wXhvhlHzM1ezz9XUXM2vXA2tTS8ejnHf8jvICog9kGspXED68_Z_ZG8BOU-wjw |
CitedBy_id | crossref_primary_10_1007_s11654_023_00512_w crossref_primary_10_1038_s41408_022_00776_5 crossref_primary_10_1007_s00277_022_05003_6 crossref_primary_10_3389_fimmu_2023_1146841 crossref_primary_10_3390_vaccines11010195 crossref_primary_10_3390_vaccines10081170 crossref_primary_10_1007_s10238_022_00964_4 crossref_primary_10_3324_haematol_2022_281484 crossref_primary_10_3390_pharmaceutics14051020 crossref_primary_10_1186_s40164_022_00315_9 crossref_primary_10_1002_ajh_27038 crossref_primary_10_1007_s10238_022_00883_4 |
Cites_doi | 10.1001/jamaoncol.2016.2437 10.1080/10428194.2019.1672053 10.1038/s41408-021-00534-z 10.1093/oxfordjournals.annonc.a058515 10.1111/bjh.14855 10.1038/s41590-020-0782-6 10.1038/s41577-021-00526-x 10.3324/haematol.2011.052829 10.1038/s41591-021-01377-8 10.1007/s10875-012-9813-x 10.1182/blood-2013-06-507947 10.1016/j.cell.2020.09.038 10.1038/s41375-020-0884-z 10.1159/000514071 10.1101/2021.08.24.21262423 10.1182/blood-2011-01-328484 10.1146/annurev.publhealth.23.100901.140546 10.1016/j.lanepe.2021.100208 10.1182/blood.2021011568 10.1038/s41586-020-2814-7 10.1172/JCI89756 10.1101/2021.03.31.21254472 10.1200/JCO.1998.16.8.2825 10.3324/haematol.2017.164285 10.1038/s41591-021-01386-7 10.1182/blood-2015-03-567388 10.1182/blood-2015-04-639203 10.1200/JCO.1997.15.10.3266 10.1016/j.leukres.2020.106432 10.1016/j.leukres.2015.11.001 |
ContentType | Journal Article |
Copyright | The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG. The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. |
Copyright_xml | – notice: The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022 – notice: 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG. – notice: The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7T5 7TK H94 K9. 7X8 5PM |
DOI | 10.1007/s10238-022-00809-0 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Immunology Abstracts Neurosciences Abstracts AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Immunology Abstracts Neurosciences Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1591-9528 |
EndPage | 379 |
ExternalDocumentID | 10_1007_s10238_022_00809_0 35352210 |
Genre | Journal Article |
GroupedDBID | --- -5E -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 203 29B 29~ 2J2 2JN 2JY 2KG 2LR 2P1 2VQ 2~H 30V 36B 3V. 4.4 406 408 409 40D 40E 53G 5VS 67Z 6NX 7X7 875 88E 8AO 8FI 8FJ 8G5 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AAFGU AAHNG AAIAL AAJKR AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADZKW AEBTG AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFEXP AFKRA AFLOW AFNRJ AFQWF AFWTZ AFZKB AGAYW AGDGC AGGBP AGJBK AGMZJ AGQMX AGWZB AGYKE AHAVH AHBYD AHIZS AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN AZQEC B-. BA0 BDATZ BENPR BGNMA BPHCQ BVXVI CAG CCPQU COF CS3 CSCUP DDRTE DL5 DNIVK DPUIP DU5 DWQXO EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNUQQ GNWQR GQ6 GQ7 GQ8 GUQSH GXS HF~ HG5 HG6 HLICF HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IKXTQ IMOTQ ITM IWAJR IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KOV KPH LAS LLZTM M1P M2O M4Y MA- MK0 N2Q N9A NB0 NPVJJ NQJWS NU0 O9- O93 O9I O9J OAM P2P P9S PF0 PQQKQ PROAC PSQYO PT4 Q2X QOR QOS R89 R9I RIG ROL RPX RSV S16 S1Z S27 S37 S3B SAP SDH SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 YLTOR Z45 Z7U Z87 ZMTXR ZOVNA AAKKN ABAKF ABEEZ ACACY ACULB ACZOJ AEFQL AFBBN AFGXO AGQEE AGRTI ALIPV C24 C6C CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION 7T5 7TK H94 K9. 7X8 5PM |
ID | FETCH-LOGICAL-c474t-f2b5e8326472b2814c324a4dc3c2a74cf2ff156d09e6d40da57049db5656dc0d3 |
IEDL.DBID | U2A |
ISSN | 1591-9528 1591-8890 |
IngestDate | Tue Sep 17 21:23:14 EDT 2024 Fri Aug 16 07:15:55 EDT 2024 Fri Sep 13 09:30:06 EDT 2024 Thu Sep 12 16:55:40 EDT 2024 Sat Sep 28 08:19:44 EDT 2024 Sat Dec 16 12:04:51 EST 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Rituximab SARS-COV-2 Vaccination Ibrutinib Cellular immune response |
Language | English |
License | 2022. The Author(s), under exclusive licence to Springer Nature Switzerland AG. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c474t-f2b5e8326472b2814c324a4dc3c2a74cf2ff156d09e6d40da57049db5656dc0d3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ORCID | 0000-0003-1241-1635 |
OpenAccessLink | https://pubmed.ncbi.nlm.nih.gov/PMC8963888 |
PMID | 35352210 |
PQID | 2819851815 |
PQPubID | 43686 |
PageCount | 9 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8963888 proquest_miscellaneous_2645471362 proquest_journals_2819851815 crossref_primary_10_1007_s10238_022_00809_0 pubmed_primary_35352210 springer_journals_10_1007_s10238_022_00809_0 |
PublicationCentury | 2000 |
PublicationDate | 2023-06-01 |
PublicationDateYYYYMMDD | 2023-06-01 |
PublicationDate_xml | – month: 06 year: 2023 text: 2023-06-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Cham |
PublicationPlace_xml | – name: Cham – name: Italy – name: Milano |
PublicationTitle | Clinical and experimental medicine |
PublicationTitleAbbrev | Clin Exp Med |
PublicationTitleAlternate | Clin Exp Med |
PublicationYear | 2023 |
Publisher | Springer International Publishing Springer Nature B.V |
Publisher_xml | – name: Springer International Publishing – name: Springer Nature B.V |
References | del PoetaGdel PrincipeMIZucchettoALucianoFBuccisanoFRossiFMCD69 is independently prognostic in chronic lymphocytic leukemia: a comprehensive clinical and biological profiling studyHaematologica20129727928710.3324/haematol.2011.052829219936673269490 YHIAAASGSLYBEfficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia BloodBlood20211373165317310.1182/blood.2021011568 DouglasAPTrubianoJABarrILeungVSlavinMATamCSIbrutinib may impair serological responses to influenza vaccinationHaematologica. Ferrata Storti Foundation2017102e397e3991:CAS:528:DC%2BC1cXitV2js73F10.3324/haematol.2017.164285 JR T, DL F. 2021. COVID-19 vaccines: modes of immune activation and future challenges. Nature reviews Immunology. Nat Rev Immunol; 21:195–7 PengYMentzerAJLiuGYaoXYinZDongDBroad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19Nat Immunol202021133613451:CAS:528:DC%2BB3cXhslCksbrF10.1038/s41590-020-0782-6328879777611020 HermanSEMGordonALHertleinERamanunniAZhangXJaglowskiSBruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765Blood Blood2011117628762961:CAS:528:DC%2BC3MXotVyhtr8%3D10.1182/blood-2011-01-32848421422473 T, H., C, P., H, P., AL, B., LA, R., F, A., et al. 2020. Convalescent plasma therapy for B-cell-depleted patients with protracted COVID-19. Blood. Blood; 136 2290-5 Solimando, A.G., Ribatti, D., Vacca, A., Einsele, H. 2016. Targeting B-cell non Hodgkin lymphoma: New and old tricks. Leukemia research [Internet]. Leuk Res; [cited 2022 Jan 25];42:93–104. Available from: https://pubmed.ncbi.nlm.nih.gov/26818572 SolmanIGBlumLKHohHYKippsTJBurgerJABarrientosJCIbrutinib restores immune cell numbers and function in first-line and relapsed/refractory chronic lymphocytic leukemiaLeukemia Research. Pergamon2020971064321:CAS:528:DC%2BB3cXhslOju7nK10.1016/j.leukres.2020.106432 KhouryDSCromerDReynaldiASchlubTEWheatleyAKJunoJANeutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infectionNat Med202127120512111:CAS:528:DC%2BB3MXhtFSktLrP10.1038/s41591-021-01377-834002089 SunCGaoJCouzensLTianXFarooquiMZEichelbergerMCSeasonal influenza vaccination in patients with chronic lymphocytic leukemia treated with IbrutinibJAMA Oncology American Medical Association201621656165710.1001/jamaoncol.2016.2437 PolackFPThomasSJKitchinNAbsalonJGurtmanALockhartSSafety and efficacy of the BNT162b2 mRNA Covid-19 vaccineMassachusetts Medical Society2020383260326151:CAS:528:DC%2BB3MXotFSjuw%3D%3D van PraetJTVandecasteeleSde RooAde VrieseASReyndersMHumoral and cellular immunogenicity of the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in nursing home residents2021Clinical Infectious DiseasesOxford University Press (OUP) MalardFGauglerBGozlanJBouquetLFofanaDSiblanyLWeak immunogenicity of SARS-CoV-2 vaccine in patients with hematologic malignanciesBlood Cancer J2021111810.1038/s41408-021-00534-z RudeliusMRosenfeldtMTLeichERauert-WunderlichHSolimandoABeilhackAInhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment. Haematologica [Internet]Ferrata Storti Foundation20181031161251:CAS:528:DC%2BC1cXisVKht73E MaloneyDGGrillo-LópezAJBodkinDJWhiteCALilesTMRoystonIIDEC-C2B8 results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphomaJ Clin Oncol199715326632741:CAS:528:DyaK2sXmslOlu7g%3D10.1200/JCO.1997.15.10.32669336364 Martínez-Gallo, M., Esperalba-Esquerra, J., Pujol-Borrell, R., Sandá, V., Arrese-Muñoz, I., Fernández-Naval, C., et al. 2021. Commercialized kit to assess T-cell responses against SARS-CoV-2 S peptides. A pilot study in Health Care Workers. medRxiv [Internet]. Cold Spring Harbor Laboratory Press; 03.31.21254472. RR G, MM P, SA A, D M, W M, AM R, et al. 2021. mRNA Vaccination induces durable immune memory to SARS-CoV-2 with continued evolution to variants of concern. bioRxiv : the preprint server for biology [Internet]. bioRxiv. SunCTianXLeeYSGuntiSLipskyAHermanSEMPartial reconstitution of humoral immunity and fewer infections in patients with chronic lymphocytic leukemia treated with ibrutinib BloodBlood2015126221322191:CAS:528:DC%2BC28XjvV2rtLo%3D10.1182/blood-2015-04-639203263374934635117 van der KolkLEBaarsJWPrinsMHvan OersMHJRituximab treatment results in impaired secondary humoral immune responsiveness BloodContent Repository Only200210022572259 EisenbergRAJawadAFBoyerJMaurerKMcDonaldKPrakETLRituximab-treated patients have a poor response to influenza vaccinationJ Clin Immunol2013333881:CAS:528:DC%2BC3sXivFCgtL4%3D10.1007/s10875-012-9813-x23064976 SahinUMuikADerhovanessianEVoglerIKranzLMVormehrMCOVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responsesNature20205865945991:CAS:528:DC%2BB3cXitV2qs7fI10.1038/s41586-020-2814-732998157 ZhuangW-HWangY-PAnalysis of the immunity effects after enhanced hepatitis B vaccination on patients with lymphomaLeuk Lymphoma20206135736310.1080/10428194.2019.167205331612751 Lumley, T., Diehr, P., Emerson, S., Chen, L. THE IMPORTANCE OF THE NORMALITY ASSUMPTION IN LARGE PUBLIC HEALTH DATA SETS. 2002 MauroFRGiannarelliDGalluzzoCMVitaleCVisentinARiemmaCResponse to the conjugate pneumococcal vaccine (PCV13) in patients with chronic lymphocytic leukemia (CLL)Leukemia20203573774610.1038/s41375-020-0884-z32555297 BadenLRel SahlyHMEssinkBKotloffKFreySNovakREfficacy and safety of the mRNA-1273 SARS-CoV-2 VaccineMassachusetts Medical Society2020384403416 LongMBeckwithKDoPMundyBLGordonALehmanAMIbrutinib treatment improves T cell number and function in CLL patientsJ Clin Investig20171273052306410.1172/JCI89756287148665531425 DubovskyJABeckwithKANatarajanGWoyachJAJaglowskiSZhongYIbrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytesBlood2013122253925491:CAS:528:DC%2BC3sXhs1CgsrfK10.1182/blood-2013-06-507947238868363795457 McLaughlinPGrillo-LópezAJLinkBKLevyRCzuczmanMSWilliamsMERituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment programProc Am Soc Clin Oncol2016162825283310.1200/JCO.1998.16.8.2825 RoekerLEKnorrDAThompsonMCNivarMLebowitzSPetersNCOVID-19 vaccine efficacy in patients with chronic lymphocytic leukemiaLeukemia Nature Publishing Group202135270327051:CAS:528:DC%2BB3MXhtFahsbnJ RM, C., SI, R., JM, D., A, G., KM, H., D, W., et al. 2020. Antigen-Specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity Cell. Cell 183:996-1012.e19. Goldberg, Y., Mandel, M., Bar-On, YM., Bodenheimer, O., Freedman, L., Haas, EJ., et al. Waning immunity of the BNT162b2 vaccine: A nationwide study from Israel. medRxiv [Internet]. Cold Spring Harbor Laboratory Press; 2021.08.24.21262423. BangeEMHanNAWileytoPKimJYGoumaSRobinsonJCD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancerNat Med202127128012891:CAS:528:DC%2BB3MXhtFehsb%2FP10.1038/s41591-021-01386-7340171378291091 Forconi, F., Moss, P. 2015. Perturbation of the normal immune system in patients with CLL. Blood. Content Repository Only! 126:573–81. P L, B E. 2021. Immune Dysfunction in Patients with Chronic Lymphocytic Leukemia and Challenges during COVID-19 Pandemic. Acta haematologica [Internet]. Acta Haematol 144. BADLSRLJAADQKBLack of adequate pneumococcal vaccination response in chronic lymphocytic leukaemia patients receiving ibrutinib. British journal of haematology [Internet]Br J Haematol201818271271410.1111/bjh.14855 BergmannLFenchelKJahnBMitrouPSHoelzerDImmunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemiaAnnals of Oncology Klmver Academic Publishers199343713751:STN:280:DyaK3szlslWrsQ%3D%3D10.1093/oxfordjournals.annonc.a058515 Naaber P, Tserel L, Kangro K, Sepp E, Adamson A, Haljasm L, et al. 2021. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study A R T I C L E I N F O. 36053341 - Clin Exp Med. 2023 Jul;23(3):955 H Y (809_CR19) 2021; 137 809_CR30 809_CR35 AADQKB BADLSRLJ (809_CR9) 2018; 182 809_CR32 FR Mauro (809_CR8) 2020; 35 M Rudelius (809_CR6) 2018; 103 C Sun (809_CR12) 2015; 126 LE Roeker (809_CR18) 2021; 35 DS Khoury (809_CR37) 2021; 27 FP Polack (809_CR16) 2020; 383 Y Peng (809_CR22) 2020; 21 JT van Praet (809_CR29) 2021 C Sun (809_CR11) 2016; 2 809_CR38 809_CR36 U Sahin (809_CR20) 2020; 586 M Long (809_CR24) 2017; 127 RA Eisenberg (809_CR15) 2013; 33 JA Dubovsky (809_CR25) 2013; 122 LR Baden (809_CR17) 2020; 384 LE van der Kolk (809_CR13) 2002; 100 809_CR21 IG Solman (809_CR34) 2020; 97 EM Bange (809_CR23) 2021; 27 G del Poeta (809_CR33) 2012; 97 DG Maloney (809_CR5) 1997; 15 809_CR1 809_CR4 L Bergmann (809_CR2) 1993; 4 SEM Herman (809_CR7) 2011; 117 AP Douglas (809_CR10) 2017; 102 W-H Zhuang (809_CR14) 2020; 61 809_CR28 809_CR27 809_CR26 P McLaughlin (809_CR3) 2016; 16 F Malard (809_CR31) 2021; 11 |
References_xml | – volume: 100 start-page: 2257 year: 2002 ident: 809_CR13 publication-title: Content Repository Only contributor: fullname: LE van der Kolk – volume: 384 start-page: 403 year: 2020 ident: 809_CR17 publication-title: Massachusetts Medical Society contributor: fullname: LR Baden – volume: 2 start-page: 1656 year: 2016 ident: 809_CR11 publication-title: JAMA Oncology American Medical Association doi: 10.1001/jamaoncol.2016.2437 contributor: fullname: C Sun – volume: 383 start-page: 2603 year: 2020 ident: 809_CR16 publication-title: Massachusetts Medical Society contributor: fullname: FP Polack – volume: 103 start-page: 116 year: 2018 ident: 809_CR6 publication-title: Ferrata Storti Foundation contributor: fullname: M Rudelius – volume: 61 start-page: 357 year: 2020 ident: 809_CR14 publication-title: Leuk Lymphoma doi: 10.1080/10428194.2019.1672053 contributor: fullname: W-H Zhuang – volume: 11 start-page: 1 year: 2021 ident: 809_CR31 publication-title: Blood Cancer J doi: 10.1038/s41408-021-00534-z contributor: fullname: F Malard – volume: 4 start-page: 371 year: 1993 ident: 809_CR2 publication-title: Annals of Oncology Klmver Academic Publishers doi: 10.1093/oxfordjournals.annonc.a058515 contributor: fullname: L Bergmann – volume: 182 start-page: 712 year: 2018 ident: 809_CR9 publication-title: Br J Haematol doi: 10.1111/bjh.14855 contributor: fullname: AADQKB BADLSRLJ – volume: 21 start-page: 1336 year: 2020 ident: 809_CR22 publication-title: Nat Immunol doi: 10.1038/s41590-020-0782-6 contributor: fullname: Y Peng – ident: 809_CR28 doi: 10.1038/s41577-021-00526-x – volume: 97 start-page: 279 year: 2012 ident: 809_CR33 publication-title: Haematologica doi: 10.3324/haematol.2011.052829 contributor: fullname: G del Poeta – volume: 27 start-page: 1205 year: 2021 ident: 809_CR37 publication-title: Nat Med doi: 10.1038/s41591-021-01377-8 contributor: fullname: DS Khoury – ident: 809_CR30 – volume: 33 start-page: 388 year: 2013 ident: 809_CR15 publication-title: J Clin Immunol doi: 10.1007/s10875-012-9813-x contributor: fullname: RA Eisenberg – volume: 122 start-page: 2539 year: 2013 ident: 809_CR25 publication-title: Blood doi: 10.1182/blood-2013-06-507947 contributor: fullname: JA Dubovsky – ident: 809_CR21 doi: 10.1016/j.cell.2020.09.038 – volume: 35 start-page: 2703 year: 2021 ident: 809_CR18 publication-title: Leukemia Nature Publishing Group contributor: fullname: LE Roeker – volume: 35 start-page: 737 year: 2020 ident: 809_CR8 publication-title: Leukemia doi: 10.1038/s41375-020-0884-z contributor: fullname: FR Mauro – ident: 809_CR32 doi: 10.1159/000514071 – ident: 809_CR38 – ident: 809_CR35 doi: 10.1101/2021.08.24.21262423 – volume: 117 start-page: 6287 year: 2011 ident: 809_CR7 publication-title: Blood Blood doi: 10.1182/blood-2011-01-328484 contributor: fullname: SEM Herman – ident: 809_CR26 doi: 10.1146/annurev.publhealth.23.100901.140546 – ident: 809_CR36 doi: 10.1016/j.lanepe.2021.100208 – volume: 137 start-page: 3165 year: 2021 ident: 809_CR19 publication-title: Blood doi: 10.1182/blood.2021011568 contributor: fullname: H Y – volume-title: Humoral and cellular immunogenicity of the BNT162b2 messenger RNA coronavirus disease 2019 vaccine in nursing home residents year: 2021 ident: 809_CR29 contributor: fullname: JT van Praet – volume: 586 start-page: 594 year: 2020 ident: 809_CR20 publication-title: Nature doi: 10.1038/s41586-020-2814-7 contributor: fullname: U Sahin – volume: 127 start-page: 3052 year: 2017 ident: 809_CR24 publication-title: J Clin Investig doi: 10.1172/JCI89756 contributor: fullname: M Long – ident: 809_CR27 doi: 10.1101/2021.03.31.21254472 – volume: 16 start-page: 2825 year: 2016 ident: 809_CR3 publication-title: Proc Am Soc Clin Oncol doi: 10.1200/JCO.1998.16.8.2825 contributor: fullname: P McLaughlin – volume: 102 start-page: e397 year: 2017 ident: 809_CR10 publication-title: Haematologica. Ferrata Storti Foundation doi: 10.3324/haematol.2017.164285 contributor: fullname: AP Douglas – volume: 27 start-page: 1280 year: 2021 ident: 809_CR23 publication-title: Nat Med doi: 10.1038/s41591-021-01386-7 contributor: fullname: EM Bange – ident: 809_CR1 doi: 10.1182/blood-2015-03-567388 – volume: 126 start-page: 2213 year: 2015 ident: 809_CR12 publication-title: Blood doi: 10.1182/blood-2015-04-639203 contributor: fullname: C Sun – volume: 15 start-page: 3266 year: 1997 ident: 809_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.1997.15.10.3266 contributor: fullname: DG Maloney – volume: 97 start-page: 106432 year: 2020 ident: 809_CR34 publication-title: Leukemia Research. Pergamon doi: 10.1016/j.leukres.2020.106432 contributor: fullname: IG Solman – ident: 809_CR4 doi: 10.1016/j.leukres.2015.11.001 |
SSID | ssj0015830 |
Score | 2.5182266 |
Snippet | Patients treated with B-cell-targeting therapies like Rituximab or Ibrutinib have decreased serological response to various vaccines. In this study, we tested... |
SourceID | pubmedcentral proquest crossref pubmed springer |
SourceType | Open Access Repository Aggregation Database Index Database Publisher |
StartPage | 371 |
SubjectTerms | Antineoplastic Combined Chemotherapy Protocols Cell-mediated immunity Chronic lymphocytic leukemia COVID-19 - etiology COVID-19 - prevention & control COVID-19 Vaccines - therapeutic use Hematology Humans Immune response (cell-mediated) Immune response (humoral) Immunity, Cellular Immunity, Humoral Internal Medicine Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphocytes B Medicine Medicine & Public Health mRNA mRNA vaccines Oncology Original Original Article Rituximab Rituximab - therapeutic use SARS-CoV-2 Serology Severe acute respiratory syndrome coronavirus 2 Vaccination γ-Interferon |
Title | Cellular and humoral immune response to SARS-CoV-2 mRNA vaccines in patients treated with either Ibrutinib or Rituximab |
URI | https://link.springer.com/article/10.1007/s10238-022-00809-0 https://www.ncbi.nlm.nih.gov/pubmed/35352210 https://www.proquest.com/docview/2819851815/abstract/ https://search.proquest.com/docview/2645471362 https://pubmed.ncbi.nlm.nih.gov/PMC8963888 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwEB6hVkJcEJRXoFSDxA0s5eE89hitWloQPWxZVE6RHTtqpG5SZbPAz2fGye52KT1wjvP8xp5vMjOfAd5n0ibWlomodFwJOVG-mERVIsJAlSnNMJkYV-V7npzO5efL-HLbx-2K3dcZSbdQ3-p1I-8iuPicWc5EUJy-z-SBTXke5pvUQZxF_tgd8-_zdj3QHVp5tzryrxSp8zwnT-DxSBkxHzB-Cg9scwAPv45J8Wfwa2qvr7maFFVj8Gq14KZ7rLnxw2I31MBa7Fu8yGcXYtp-FyEuZuc5_lQlX2GJdYOjvuoSXeW5Ncg_aNFyx0aHZ7oj-2xqjW2Hs7pf_a4XSj-H-cnxt-mpGPdTEKVMZS-qUMeWZjArxuswC2RJbEpJU0ZlqFJZVmFVUThn_IlNjPSNilOKH4xmzmdK30QvYK9pG_sK0DdBpiJDZI_cm9IVBW3k6HyrlEystJEHH9bfuLgZZDOKrUAyI1IQIoVDpPA9OFzDUIxTaFlwho_oYBbEHrzbHCbj54yGamy7ojFOjywgJ-zBywG1ze0iFq6hgNaDdAfPzQAW1t490tRXTmA741Upyzz4uEZ--1j3v8Xr_xv-Bh7x1vVD2dkh7PXdyr4lgtPrI9jPP_34cnzkDPsPkbv1sw |
link.rule.ids | 230,315,786,790,891,27957,27958,41116,41558,42185,42627,52146,52269 |
linkProvider | Springer Nature |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9NAEB6hVAIu5V0MBQaJG2zlx_qRYxS1pLTNIW1QOVn7smrR2JXjAOLXM-tHSlo49Lxre707u_ON55vPAB8SbiJjVMQyGWaMD4XLhkEWMd8TKqYdxiPdsHyn0WTOv5yH511R2LJnu_cpyeak_qvYjdwLs-xzC3OGjAL1LU4eKhzA1ujzt6P9dfYgTAK3K5D595WbTugWsrxNkLyRJW2cz8EjmPfDbjkn3_dWtdxTv28oOt71vR7DdodGcdSazxO4Z4qncP-ky7c_g59jc3lpiaooCo0Xq4Wt58fc1pQYrFp6rcG6xNPR7JSNy6_Mx8VsOsIfQtk7LDEvsJNuXWJDajca7bdfNLYYpMJDWZHpF7nEssJZXq9-5Qshn8P8YP9sPGHdrxqY4jGvWebL0NDhYMXopZ94XBFQE1yrQPki5irzs4wiRe0OTaS5q0UYU2iipYWTWrk6eAGDoizMS0BXe4kINOFI8pxCZhQPkg91jRA8MtwEDnzs1y69ahU50mvtZTuXKc1l2sxl6jqw2y9v2u3OZWqTh4Q0Ey904P26mfaVTZaIwpQr6tNInXnk3x3Yaa1h_bjAauJQrOxAvGEn6w5Ws3uzpcgvGu3uxB54SeLAp94Yrof1_7d4dbfu7-DB5OzkOD0-nB69hoc-tbfstl0Y1NXKvCEcVcu33bb5AziaFHQ |
linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3JbtRAEC2hRIq4sC-GAI3EDTrx0l7mOBoyJARGaEJQOFm9KhaZduSxAfH1VHuZZBI4IM7dXrpd5XrlevUM8CpjOtFaJtSI2FA24j4dRSahYcBlih7GEtWyfGfJ_jF7fxKfXOrib9nuQ0my62lwKk223j1XZvdS4xuGGuqY6A7yjCgm7ZsM3RZtfHP87uvh3qqSEGeR3zfL_PnI9YB0DWVeJ0teqZi2gWh6G_iwhI5_8m2nqcWO_HVF3fF_1ngHbvUolYw7s7oLN7S9B1sf-zr8ffgx0WdnjsBKuFXktFm4Pn9SuF4TTaqOdqtJXZKj8fyITsovNCSL-WxMvnPpzrAkhSW9pOuStGR3rYj7Jky0axKpyIGo0CVsIUhZkXlRNz-LBRcP4Hi693myT_tfOFDJUlZTE4pY40vDidSLMAuYRADHmZKRDHnKpAmNwQxS-SOdKOYrHqeYsijhYKaSvooewoYtrX4MxFdBxiOF-BIjKhcG80SMrb7mnCWa6ciD18NzzM87pY78QpPZ7WWOe5m3e5n7HmwPjzrvvXaZu6IiItAsiD14uRpGf3NFFG512eCcVgItwLjvwaPOMlaXi5xWDubQHqRrNrOa4LS810dscdpqemfuRZhlHrwZDOPitv6-iif_Nv0FbH16O80_HMwOn8LNEIc70ts2bNRVo58hvKrF896DfgOdnx1P |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cellular+and+humoral+immune+response+to+SARS-CoV-2+mRNA+vaccines+in+patients+treated+with+either+Ibrutinib+or+Rituximab&rft.jtitle=Clinical+and+experimental+medicine&rft.au=Bacova%2C+Barbora&rft.au=Kohutova%2C+Zuzana&rft.au=Zubata%2C+Ivana&rft.au=Gaherova%2C+Lubica&rft.date=2023-06-01&rft.eissn=1591-9528&rft.volume=23&rft.issue=2&rft.spage=371&rft_id=info:doi/10.1007%2Fs10238-022-00809-0&rft_id=info%3Apmid%2F35352210&rft.externalDocID=35352210 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1591-9528&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1591-9528&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1591-9528&client=summon |